CTHRC1 Abiomarker in Rheumatoid Arthritis Diagnosis

Rheumatoid Arthritis Clinical Trial

Official title:

CTHRC1 Apromising Biomarker in Rheumatoid Arthritis Diagnosis

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04085471
• Other study ID #: rheumatoid arthritis
• Status: Not yet recruiting
• Start date: October 1, 2019
• Est. completion date: December 1, 2020

Study information

• Verified date: September 2019
• Source: Assiut University
• Contact: Lobna Amer Araby, Master
• Phone: 01019313530
• Email: lobnaamer20[@]gmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of the study is to determine whether plasma levels of the collagen triple helix repeat containing (CTHRC1) protein can serve as a blood-based biomarker for diagnosis of rheumatoid arthritis (RA) ,and furthermore its correlation with disease activity.

Description:

Rheumatoid arthritis (RA) is a chronic, progressive, autoimmune disease of synovial joints. Characterized by periods of flares with high disease activity involving both a systemic immune response and tissue-specific inflammatory events that can lead to erosive joint and bone destruction and subsequent disability . Currently, diagnosis of RA is based mainly on the extent of tenderness and swelling of the joints , levels of acute-phase reactants such as C-reactive protein (CRP) ,erythrocyte sedimentation rate(ESR) , high titers of rheumatoid factor (RF) and high titers of antibodies against cyclic citrullinated peptide (anti-CCP) in the plasma .Of interest, CTHRC1 is a secreted modulator of Wnt signaling, which is a key regulator of joint remodeling, and promotes cell proliferation and migration. Therefore, CTHRC1 may contribute to multiple aspects of the pathogenic FLS behavior in RA and modulate processes that promote synovial hyperplasia and invasion.The expression pattern of CTHRC1 in pannus, its role in the function of FLS relevant to cartilage damage in RA, and CTHRC1's association with disease severity in murine arthritis raised the question of whether CTHRC1 could be used as a marker for RA diagnosis and monitoring of disease activity in patients

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 90
• Est. completion date: December 1, 2020
• Est. primary completion date: October 1, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• -Patients diagnosed as RA.

• Patients ( >18)who are age and sex matched with the controls

Exclusion Criteria:

. Other Rheumatologic diseases. .Patients with malignancy . .Patients with hepatic disease .

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid
• Rheumatoid Arthritis

Intervention

Diagnostic Test:
• CTHRC1 biomarker level in rheumatoid arthritis
measurment of levels of CTHRC1 in patients diagnosed as RA

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

References & Publications (1)

Myatt GL, Ecobichon DJ, Greenhalgh R. Fenitrooxon and S-methyl fenitrothion: acute toxicity and hydrolysis in mammals. Environ Res. 1975 Dec;10(3):407-14. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	CTHRC1 Apromising biomarker in rheumatoid arthritis diagnosis	measurement of levels of CTHRC1 in rheumatoid arthritis patients	one year